SG11201503395TA - ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFNα - Google Patents

ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFNα

Info

Publication number
SG11201503395TA
SG11201503395TA SG11201503395TA SG11201503395TA SG11201503395TA SG 11201503395T A SG11201503395T A SG 11201503395TA SG 11201503395T A SG11201503395T A SG 11201503395TA SG 11201503395T A SG11201503395T A SG 11201503395TA SG 11201503395T A SG11201503395T A SG 11201503395TA
Authority
SG
Singapore
Prior art keywords
ifnα
modulation
compounds useful
alkyl amide
pyrimidine compounds
Prior art date
Application number
SG11201503395TA
Other languages
English (en)
Inventor
Joseph B Santella
Ryan M Moslin
David S Weinstein
Stephen T Wrobleski
John S Tokarski
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SG11201503395TA publication Critical patent/SG11201503395TA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/95Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Enzymes And Modification Thereof (AREA)
SG11201503395TA 2012-11-08 2013-11-07 ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFNα SG11201503395TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261723827P 2012-11-08 2012-11-08
PCT/US2013/068866 WO2014074670A1 (en) 2012-11-08 2013-11-07 ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFNα

Publications (1)

Publication Number Publication Date
SG11201503395TA true SG11201503395TA (en) 2015-05-28

Family

ID=49667570

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201503395TA SG11201503395TA (en) 2012-11-08 2013-11-07 ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFNα

Country Status (14)

Country Link
US (1) US9540333B2 (zh)
EP (1) EP2917186B1 (zh)
JP (1) JP6266639B2 (zh)
KR (1) KR102205914B1 (zh)
CN (1) CN104903301B (zh)
AU (1) AU2013341195B2 (zh)
BR (1) BR112015009798A2 (zh)
CA (1) CA2890935A1 (zh)
EA (1) EA028052B1 (zh)
ES (1) ES2648226T3 (zh)
IL (1) IL238605A (zh)
MX (1) MX2015005561A (zh)
SG (1) SG11201503395TA (zh)
WO (1) WO2014074670A1 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3495358T3 (pl) 2012-11-08 2022-06-27 Bristol-Myers Squibb Company Podstawione amidem związki heterocykliczne przydatne jako modulatory odpowiedzi il-12, il-23 i/lub ifn-alfa
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
US10273237B2 (en) 2013-12-10 2019-04-30 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN-α responses
JP7145850B2 (ja) * 2016-10-28 2022-10-03 ブリストル-マイヤーズ スクイブ カンパニー Il-12、il-23および/またはifnアルファ応答の調節剤として有用なヘテロ二環化合物
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
CN107857754B (zh) * 2018-01-15 2018-11-09 泰山医学院 一种化合物及其在制备预防/治疗类风湿性关节炎药物中的应用
CA3090842A1 (en) 2018-03-12 2019-09-19 Abbvie Inc. Inhibitors of tyrosine kinase 2 mediated signaling
TWI721483B (zh) 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
EP3962475A1 (en) 2019-04-30 2022-03-09 Celgene Corporation Combination therapies comprising apremilast and tyk2 inhibitors
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
WO2022175752A1 (en) 2021-02-19 2022-08-25 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
WO2023076161A1 (en) 2021-10-25 2023-05-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US7449456B2 (en) * 2002-06-28 2008-11-11 Astellas Pharma, Inc. Diaminopyrimidinecarboxamide derivative
KR20050019797A (ko) * 2002-06-28 2005-03-03 야마노우치세이야쿠 가부시키가이샤 디아미노피리미딘카르복사미드 유도체
JP5046943B2 (ja) * 2004-09-30 2012-10-10 テイボテク・フアーマシユーチカルズ Hiv阻害性5−置換ピリミジン
WO2006068770A1 (en) * 2004-11-24 2006-06-29 Rigel Pharmaceuticals, Inc. Spiro-2, 4-pyrimidinediamine compounds and their uses
JP5078986B2 (ja) * 2006-03-30 2012-11-21 テイボテク・フアーマシユーチカルズ Hivを阻害する5−アミド置換されたピリミジン
CN101506177A (zh) * 2006-07-21 2009-08-12 诺瓦提斯公司 作为jak激酶抑制剂的2,4-二(芳基氨基)-嘧啶-5-酰胺化合物
EP2323993B1 (en) * 2008-04-16 2015-06-03 Portola Pharmaceuticals, Inc. 2,6-diamino- pyrimidin- 5-yl-carboxamides as syk or jak kinases inhibitors
CN102066340B (zh) * 2008-04-16 2014-05-14 波托拉医药品公司 作为syk或jak蛋白激酶抑制剂的2,6-二氨基-嘧啶-5-基甲酰胺类化合物
US20110071158A1 (en) * 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
WO2010129802A1 (en) * 2009-05-06 2010-11-11 Portola Pharmaceuticals, Inc. Inhibitors of jak
US8586751B2 (en) * 2009-06-12 2013-11-19 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
WO2011065800A2 (ko) * 2009-11-30 2011-06-03 주식회사 오스코텍 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물
TWI681952B (zh) * 2011-04-22 2020-01-11 美商標誌製藥公司 經取代之二胺基甲醯胺及二胺基甲腈嘧啶、其組合物、及以該等治療之方法
PL3495358T3 (pl) 2012-11-08 2022-06-27 Bristol-Myers Squibb Company Podstawione amidem związki heterocykliczne przydatne jako modulatory odpowiedzi il-12, il-23 i/lub ifn-alfa
EP2922841B8 (en) 2012-11-08 2017-08-02 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa

Also Published As

Publication number Publication date
KR20150079678A (ko) 2015-07-08
ES2648226T3 (es) 2017-12-29
WO2014074670A1 (en) 2014-05-15
EP2917186A1 (en) 2015-09-16
MX2015005561A (es) 2015-07-23
IL238605A (en) 2017-05-29
JP6266639B2 (ja) 2018-01-24
CN104903301A (zh) 2015-09-09
IL238605A0 (en) 2015-06-30
EP2917186B1 (en) 2017-10-18
US9540333B2 (en) 2017-01-10
JP2016501185A (ja) 2016-01-18
KR102205914B1 (ko) 2021-01-20
BR112015009798A2 (pt) 2017-07-11
AU2013341195B2 (en) 2017-09-21
EA201590911A1 (ru) 2015-10-30
EA028052B1 (ru) 2017-10-31
AU2013341195A1 (en) 2015-07-02
CN104903301B (zh) 2017-08-29
CA2890935A1 (en) 2014-05-15
US20150299139A1 (en) 2015-10-22

Similar Documents

Publication Publication Date Title
HUS2300025I1 (hu) Amidszubsztituált heterociklikus vegyületek mint IL-12, IL-23 és/vagy IFN-ALFA modulátorai
IL238605A0 (en) Alkyl amide-modified pyrimidine compounds for use in il-23, il-12, and/or ifnα modulation
IL238554A0 (en) Alkyl-amide substituted pyridyl compounds are useful as modulators of il12, il23, and/or ifnα responses
IL253950B (en) Cyclic-converted uracils and their use
HK1219852A1 (zh) 加熱或冷卻式餐具及飲具
HK1202050A1 (zh) 凍干以及水性抗 抗體制劑
EP3083606A4 (en) Pyrimidines and use thereof
GB201318787D0 (en) Upconverting vehicles and uses
IL241823B (en) Preparations containing novyi .c and their uses for the treatment of cancerous tumors
EP3046417A4 (en) METHOD OF USING ADIPOSE TISSUE DERIVED CELLS IN THE MODULATION OF PAIN AND / OR FIBROSIS
HK1175159A1 (zh) 種石墨塊材料及其製備方法
EP3036849A4 (en) Bs and ue, and methods used in the same
EP2747777A4 (en) ROTAVIRUS PREPARATIONS WITH EXCESSIVE CALCIUMIONES AND HIGH VISCOSITY TO ENSURE VACCINITY OF THE VACCINE AT HIGH TEMPERATURES
AU2013902966A0 (en) Improvements in shoes and the like